BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…
Full product line of TrinaTracker Vanguard series now Carbon Footprint certified
CHANGZHOU, China, Oct. 2, 2025 /PRNewswire/ -- TrinaTracker, a provider of smart…
WEB3 Meets Edtech as Geninfinity Introduces Blockchain Identity Tools for All Users
Geninfinity introduces a secure system that lets users create digital identities and…
